BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
62.87
+0.13 (0.21%)
Apr 25, 2025, 12:36 PM EDT - Market open
BioMarin Pharmaceutical Revenue
In the year 2024, BioMarin Pharmaceutical had annual revenue of $2.85B with 17.97% growth. BioMarin Pharmaceutical had revenue of $747.31M in the quarter ending December 31, 2024, with 15.65% growth.
Revenue (ttm)
$2.85B
Revenue Growth
+17.97%
P/S Ratio
4.18
Revenue / Employee
$938,788
Employees
3,040
Market Cap
12.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
BMRN News
- 8 days ago - BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET - PRNewsWire
- 21 days ago - BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion - Seeking Alpha
- 23 days ago - BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria - PRNewsWire
- 5 weeks ago - BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting - PRNewsWire
- 2 months ago - BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA - PRNewsWire
- 2 months ago - BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors - PRNewsWire
- 2 months ago - Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga
- 2 months ago - BioMarin Pharmaceutical Inc. (BMRN) Q4 2024 Earnings Call Transcript - Seeking Alpha